Advertisement
Advertisement
Trending on Dermatology Times
1
Filling the HS Treatment Gap: Ruxolitinib Targets Early-Stage Disease
2
Lebrikizumab Earns FDA Approval for Less Frequent, Every-8-Week Maintenance Dosing in AD
3
Social Media Mythbusters: Skin Cycling
4
Semaglutide, Tirzepatide Flag Alopecia Signals in 10-Year FAERS Review
5